Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients (Q57601819)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

10 March 2020

main subject

multiple sclerosis

0 references

0 references

author

Jordi Rio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Mar Tintoré

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jaume Sastre Garriga

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Carmen Tur

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Xavier Montalban

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Alex Rovira

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Joaquín Castilló

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Cristina Auger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Carlos Nos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Manuel Comabella

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ángela Vidal

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

12 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1602-1608

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

Multiple sclerosis: current treatment algorithms.

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Predicting responders to therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Scoring treatment response in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

A solution to the problem of separation in logistic regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514527863

21 January 2018

Identifiers

DOI

10.1177/1352458514527863

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622350%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference